Form 4: Oruka General Counsel Sells Shares for Tax Obligations

Oruka Therapeutics' General Counsel, Paul T. Quinlan, sold 733 shares of common stock at $41.3 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Paul T. Quinlan, General Counsel of Oruka Therapeutics, Inc. (ORKA), reported a transaction involving the company's common stock.
• On March 16, 2026, Mr. Quinlan disposed of 733 shares of common stock.
• The shares were sold at a price of $41.3 per share.
• The sale was executed as part of Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units.
• Following this transaction, Mr. Quinlan beneficially owns 31,767 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The transaction is a routine, non-discretionary sale to cover tax obligations on RSU vesting and does not reflect a change in the insider's investment sentiment or the company's operational performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions, like the one reported, are a common and routine practice for executives to manage tax liabilities associated with the vesting of equity awards such as restricted stock units. These non-discretionary sales are typically pre-arranged and are generally not indicative of an insider's discretionary view on the company's future stock performance or operational health.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction by an insider to cover tax obligations, not a discretionary sale based on a change in company outlook.

Key Dates

Recommendation

The transaction is a routine, non-discretionary 'sell-to-cover' to satisfy tax obligations on RSU vesting, which does not reflect a change in the insider's view of the company's prospects or warrant a change in investment recommendation. No new material information affecting the company's fundamentals or strategic direction is presented.

Keywords

Oruka Therapeutics, ORKA, Form 4, Insider Transaction, Stock Sale, Paul Quinlan, General Counsel, Restricted Stock Units, Tax Withholding